UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	D	ate of Report (date of earliest event reported	d): July 27, 2023
		InfuSystem Holdings, Inc (Exact name of registrant as specified in i	
	Delaware (State or other jurisdiction of incorporation or organization)	001-35020 (Commission File Number)	20-3341405 (I.R.S. Employer Identification Number)
		3851 West Hamlin Road Rochester Hills, Michigan 4830	9
		(Address of principal executive offices) ((Zip Code)
		(248) 291-1210	
		(Registrant's telephone number, including	area code)
		Not Applicable	
	(F	ormer Name or Former Address, if Changed S	ince Last Report)
	Written communications pursuant to Rule 425 Soliciting material pursuant to Rule 14a-12 un Pre-commencement communications pursuant Pre-commencement communications pursuant	der the Exchange Act (17 CFR 240.14a-12) to Rule 14d-2(b) under the Exchange Act (17	CFR 240.13e-4(c))
	Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value \$.0001 per share		INFU	NYSE American LLC
of the Se Em	ecurities Exchange Act of 1934 ($\S240.12b-2$ of th erging growth company \square	mark if the registrant has elected not to use	05 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 the extended transition period for complying with any new or revised

Item 7.01 - Regulation FD

On July 27, 2023, InfuSystem Holdings, Inc. (the "Company") issued a press release announcing that the Company will disclose its financial results for the second quarter 2023 on Thursday, August 3, 2023 before the market opens. The Company will also conduct a conference call for all interested investors on Thursday, August 3, 2023 at 9:00 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 7.01 — "Regulation FD Disclosure" of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of InfuSystem Holdings, Inc. dated July 27, 2023

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Richard DiIorio

Richard DiIorio

Chief Executive Officer and Director

Dated: July 27, 2023



InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210

FOR IMMEDIATE RELEASE

CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700

InfuSystem to Report Second Quarter 2023 Financial Results on August 3, 2023

Investor Conference Call to be held 9:00 a.m. Eastern Time

Rochester Hills, Michigan, July 27, 2023 — InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2023 financial results on Thursday, August 3, 2023, before the market opens.

The Company will also conduct a conference call for all interested parties on Thursday, August 3, 2023 at 9:00 a.m. Eastern Time to discuss its financial results

To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company's website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, replay access code 9921883 through Thursday, August 10, 2023.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Patient Services (formerly Integrated Therapy Services ("ITS")), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Device Solutions (formerly Durable Medical Equipment Services ("DME Services")), supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

####